Role of Medical Management for Uterine Leiomyomas

Best Pract Res Clin Obstet Gynaecol. 2016 Jul:34:85-103. doi: 10.1016/j.bpobgyn.2015.11.016. Epub 2015 Nov 25.

Abstract

Uterine leiomyomas, or fibroids, are the most common benign tumor in reproductive aged women. Affected women may remain asymptomatic or may report symptoms related to abnormal uterine bleeding, infertility, or pelvic pain and pressure. Depending on a patient's symptomatology and reproductive plans, treatment options include expectant management, medical management (hormonal and non-hormonal), or surgical management (myomectomy or hysterectomy). In those wishing to defer surgical management, non-hormonal therapies such as non-steroidal anti-inflammatory drugs and tranexamic acid have been shown to decrease menstrual blood loss. In patients with more symptomatic leiomyomas, hormonal therapies such as gonadotropin-releasing hormone agonists and selective progesterone receptor modulators are effective at reducing leiomyoma volume, uterine size, and menstrual blood loss. This manuscript will detail the available and emerging hormonal and non-hormonal treatments for symptomatic uterine leiomyomas.

Keywords: abnormal uterine bleeding; fibroids; medical management; uterine leiomyomas.

Publication types

  • Review

MeSH terms

  • Antifibrinolytic Agents / therapeutic use
  • Aromatase Inhibitors / therapeutic use
  • Cabergoline
  • Cholecalciferol / therapeutic use
  • Contraceptive Agents, Female / administration & dosage
  • Contraceptive Agents, Female / therapeutic use*
  • Contraceptives, Oral, Hormonal / therapeutic use
  • Contraceptives, Oral, Synthetic / therapeutic use
  • Danazol / therapeutic use
  • Dopamine Agonists / therapeutic use
  • Ergolines / therapeutic use
  • Estrenes / therapeutic use
  • Estrogen Antagonists / therapeutic use
  • Female
  • Gestrinone / therapeutic use
  • Gonadotropin-Releasing Hormone / agonists*
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Humans
  • Intrauterine Devices, Medicated
  • Leiomyoma / drug therapy*
  • Levonorgestrel / administration & dosage
  • Mifepristone / therapeutic use
  • Norpregnadienes / therapeutic use
  • Oximes / therapeutic use
  • Patient Care Planning
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Somatostatin / analogs & derivatives
  • Tranexamic Acid / therapeutic use
  • Uterine Neoplasms / drug therapy*
  • Vitamins / therapeutic use

Substances

  • Antifibrinolytic Agents
  • Aromatase Inhibitors
  • Contraceptive Agents, Female
  • Contraceptives, Oral, Hormonal
  • Contraceptives, Oral, Synthetic
  • Dopamine Agonists
  • Ergolines
  • Estrenes
  • Estrogen Antagonists
  • Norpregnadienes
  • Oximes
  • Selective Estrogen Receptor Modulators
  • Vitamins
  • Gestrinone
  • Cholecalciferol
  • Mifepristone
  • Gonadotropin-Releasing Hormone
  • Somatostatin
  • Levonorgestrel
  • Tranexamic Acid
  • asoprisnil
  • Cabergoline
  • Danazol
  • ulipristal acetate